Stephen Dyar
Mayo Clinic
5 Papers
46 Citations
Stephen Dyar is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
A nurse practitioner directed intervention improves the quality of life of patients with metastatic cancer: results of a randomized pilot study.
TL;DR: An ARNP-directed intervention that explains the benefits of hospice and addresses advanced directives early in the course of metastatic cancer patients' treatment, is well received by the patients and their relatives and leads to measurable improvement in the patient's emotional and mental QoL.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
Alvaro Moreno-Aspitia,David W. Hillman,Stephen Dyar,Kathleen S. Tenner,Julie R. Gralow,Peter A. Kaufman,Nancy E. Davidson,Jacqueline M. Lafky,Monica M. Reinholz,Wilma L. Lingle,Leila A. Kutteh,Walter P. Carney,Amylou C. Dueck,Edith A. Perez +13 more
TL;DR: In this article, the authors evaluated levels of sHER2 during treatment and at the time of disease recurrence in the adjuvant North Central Cancer Treatment Group N9831 clinical trial.
54
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
Gabriela Galffy,Iwona Lugowska,Elena Poddubskaya,Byoung Chul Cho,M. Ahn,Jy Han,Wu Chou Su,Ralph J. Hauke,Stephen Dyar,D.H. Lee,Piotr Serwatowski,David Lorente Estelles,Viran R. Holden,Y.J. Kim,Vladimir Vladimirov,Zsolt Horváth,Apurba Ghose,Allison Goldman,Alessandra di Pietro,J. Wang,Danielle Murphy,Ali A. Alhadab,Mikhail Laskov +22 more
TL;DR: Avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC) as discussed by the authors .
4
Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.
Stephen Dyar,Alvaro Moreno-Aspitia +1 more
- 28 Nov 2011
TL;DR: The use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.
3
Triple-negative breast cancer and new treatment developments
TL;DR: Agents targeting aberrant DNA repair, including platinum and PARP-1 inhibitors, are under evaluation in TNBC based on its overlap with BRCA1-related breast cancer.